Pioneering Vaccine Trials: Unveiling the Science Behind Neutralizing Antibody Assessment

Pioneering Vaccine Trials: Unveiling the Science Behind Neutralizing Antibody Assessment

In the realm of public health, where the importance of viral vaccines continues to grow, large-scale vaccine trials stand as linchpins in safeguarding the well-being of millions, if not millions, worldwide.  At the heart of evaluating vaccine efficacy and safety lies the indispensable Neutralizing Antibody (NAb) assay, particularly the biologically potent cell-based approaches. 

Neutralizing antibodies (NAb) can be a critical component to assessing safety in therapeutic drug trials or efficacy in vaccine trials. This bulletin highlights the utility of using cell-based neutralizing antibody assays and provides insights on some best practices for industry use where high-throughput capacity and reliable reproducibility are required.